TORRENT PHARMACEUTICALS LTD. - 500420 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of Loss of Share Certificates03-07-2023
03-07-2023
TORRENT PHARMACEUTICALS LTD. - 500420 - Closure of Trading Window
Intimation of Closure of Trading Window as per Company''s Code of Conduct to Regulate, Monitor and Report Trading by Designated Persons29-06-2023
TORRENT PHARMACEUTICALS LTD. - 500420 - USFDA Pre-Approval Inspection Of Oral Oncology Manufacturing Facility, Gujarat
We refer to our earlier letter dated 17-Mar-23 regarding USFDA Pre- Approval Inspection [PAI] of our Oral- Oncology manufacturing facility at Bileshwarpura, Gujarat. In furtherance to the aforementioned intimation, this is to inform you that USFDA has issued an Establishment Inspection Report (EIR) for the said manufacturing facility and the inspection has now been successfully closed by the USFDA. Please take the information on record.15-06-2023
TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
In continuation of our letter dated 16-May-23 and pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Transcript of Conference call with Analysts / Investors on Audited Financial Results of the Company for the quarter and year ended 31st March, 2023, has been placed on the Company's website at https://www.torrentpharma.com/pdf/investors/Earnings_Call_Transcript_May_30_2023.pdf03-06-2023
Hold Torrent Pharmaceuticals; target of Rs 1910: Sharekhan
Sharekhan recommended Hold rating on Torrent Pharmaceuticals with a target price of Rs 1910 in its research report dated May 31, 2023.01-06-2023
Torrent Pharma: Synergy benefits, products launches are key
However, the company's March quarter (Q4FY23) results are broadly in line with Street estimates. Analysts say stable margin last quarter, expected gains from Curatio integration and new product launches are reasons for optimism.01-06-2023
Torrent Pharma share price surges 8% to hit a 52-week high; should you buy the stock? Here's what top brokerages say
Torrent Pharmaceuticals' share price surged 8 per cent to hit a 52-week high of 1,851.15 after reporting Q4 net revenue of 2,491 crore, up 17 per cent YoY, and a net profit of 287 crore, compared with a net loss of 118 crore in the previous year.31-05-2023
TORRENT PHARMACEUTICALS LTD. - 500420 - Audio Recording Of Conference Call With Analysts / Investors On Audited Financial Results For The Quarter And Year Ended 31St March, 2023
In continuation to our letter dated 16-May-23 and pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the audio recording of Conference call with Analysts / Investors on Audited Financial Results of the Company for the quarter and year ended 31st March, 2023, has been placed on the Company's website at https://www.torrentpharma.com/pdf/investors/Audio_Recording31032023.mp330-05-2023
Torrent Pharmaceuticals Results Earnings Call for Q4FY23
Conference Call with Torrent Pharmaceuticals Management and Analysts on Q4FY23 Performance and Outlook. Listen to the full earnings transcript.30-05-2023
Q4FY23 Quarterly & FY23 Annual Result Announced for Torrent Pharmaceuticals Ltd.
Torrent Pharmaceuticals announced Q4FY23 results: Q4FY23: Revenue at Rs 2,491 crore up by 17% Gross margins: 72%; Op. EBITDA margins: 29.2% Op. EBITDA at Rs 727 crore was up by 30% Profit after tax at Rs 287 crore FY23: Revenue at Rs 9,620 crore up by 13% Gross margins: 71%; Op. EBITDA margins: 29% Op. EBITDA at Rs 2,842 crore was up by 17% Profit after tax at Rs 1,245 crore Result PDF30-05-2023